GSK Decreases Reliance On Late-Stage Licenses, Citing Strength In R&D

GlaxoSmithKline is reducing its reliance on late-stage in-licensing deals following an R&D restructuring program that has yielded a burgeoning pipeline, CEO J.P. Garnier told analysts